Andere talen Cyxone AB

Aandelen

Beurs gesloten - Nasdaq Stockholm Andere beurzen 18:00:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,11 ^SEK	0,00%		-16,67%	+9,56%

14/05	Cyxone AB (publ) rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2024	CI
22/04	Cyxone AB (publ) kondigt wijzigingen aan in CEO	CI

Cyxone AB Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Sweden's Cyxone Appoints New CEO	22/04
Kjell Stenberg new CEO in Cyxone AB	22/04
Cyxone AB Announces Chief Executive Officer Changes	22/04
BioStock: Cyxone comments on the clinical collaboration in the UK	28/03
Cyxone Enters Research Deal for Rheumatoid Arthritis Therapy	25/03
Cyxone enters important research collaboration	25/03
Cyxone Enters Important Research Collaboration with University of Glasgow	25/03
BioStock: Cyxone's CEO gives a status update	05/03
Cyxone AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
BioStock: Cyxone identifies target protein for rabeximod	17/01
Cyxone reaches important milestone regarding mechanism of action	15/01
Cyxone Reaches an Important Milestone for the Drug Candidate Rabeximod	15/01
Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor	20/11
Interim Report 1 January to 30 September 2023	27-10-23
Cyxone AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27-10-23
Cyxone to Receive Unitary Patent in EU for T20K Drug Candidate	09-10-23
Cyxone receives Intention to Grant from the European Patent Office for a unitary patent of T20K	09-10-23
BioStock Investor Meeting: Cyxone	27-09-23
Interim Report 1 January to 30 June 2023	30-08-23

Geen resultaten voor deze zoekopdracht